These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26487643)

  • 21. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
    Verstovsek S; Manshouri T; Smith FO; Giles FJ; Cortes J; Estey E; Kantarjian H; Keating M; Jeha S; Albitar M
    Cancer; 2003 May; 97(9):2212-7. PubMed ID: 12712473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia.
    Tang X; Chen L; Yan X; Li Y; Xiong Y; Zhou X
    Med Sci Monit; 2015 Nov; 21():3427-33. PubMed ID: 26549593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.
    Brown FC; Still E; Koche RP; Yim CY; Takao S; Cifani P; Reed C; Gunasekera S; Ficarro SB; Romanienko P; Mark W; McCarthy C; de Stanchina E; Gonen M; Seshan V; Bhola P; O'Donnell C; Spitzer B; Stutzke C; Lavallée VP; Hébert J; Krivtsov AV; Melnick A; Paietta EM; Tallman MS; Letai A; Sauvageau G; Pouliot G; Levine R; Marto JA; Armstrong SA; Kentsis A
    Cancer Discov; 2018 Apr; 8(4):478-497. PubMed ID: 29431698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
    Gerbing RB; Alonzo TA; Sung L; Gamis AS; Meshinchi S; Plon SE; Bertuch AA; Gramatges MM
    J Clin Oncol; 2016 Nov; 34(31):3766-3772. PubMed ID: 27354474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of renin expression by real-time PCR in acute myeloid leukemia.
    Iñigo Sde L; Casares MT; Jorge CE; Leiza SM; Santana GS; Bravo de Laguna SJ; San Miguel JD; Caballero A; Alvarez Mdel M; Castellano AL; Henríquez HL; Labarta TM
    Leuk Lymphoma; 2006 Mar; 47(3):409-16. PubMed ID: 16396763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
    Marcucci G; Baldus CD; Ruppert AS; Radmacher MD; Mrózek K; Whitman SP; Kolitz JE; Edwards CG; Vardiman JW; Powell BL; Baer MR; Moore JO; Perrotti D; Caligiuri MA; Carroll AJ; Larson RA; de la Chapelle A; Bloomfield CD
    J Clin Oncol; 2005 Dec; 23(36):9234-42. PubMed ID: 16275934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical significance of real-time fluorescence PCR quantification of hepatocyte growth factor mRNA expression in acute leukemia].
    Cen D; Lü JX; Pei RZ; Tu ZG; Yu XL; Wen YA
    Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):401-4. PubMed ID: 18953951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
    Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
    Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
    Roberson JR; Onciu M; Pounds S; Rubnitz JE; Pui CH; Razzouk BI
    Pediatr Blood Cancer; 2008 Mar; 50(3):542-8. PubMed ID: 17763467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocyte enhancer factor 2C in hematopoiesis and leukemia.
    Canté-Barrett K; Pieters R; Meijerink JP
    Oncogene; 2014 Jan; 33(4):403-10. PubMed ID: 23435431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
    Ho PA; Kuhn J; Gerbing RB; Pollard JA; Zeng R; Miller KL; Heerema NA; Raimondi SC; Hirsch BA; Franklin JL; Lange B; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2011 Feb; 29(6):704-11. PubMed ID: 21189390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.